157322-83-3

Usage

Uses

Used in Pharmaceutical Industry:
Eribulin mesylate intermediate is used as a key intermediate in the synthesis of Eribulin mesylate for its potent anticancer properties. It is particularly effective against various types of solid malignancies, including breast, lung, and pancreatic cancers. The intermediate plays a vital role in the development of Eribulin mesylate, which has been shown to modulate multiple oncological signaling pathways, leading to the inhibition of tumor growth and progression.
Additionally, Eribulin mesylate intermediate contributes to the development of drug delivery systems that aim to enhance the bioavailability and therapeutic outcomes of Eribulin mesylate. Various organic and metallic nanoparticles have been employed as carriers for the delivery of Eribulin mesylate, improving its efficacy and overcoming limitations associated with its use in cancer treatment.

Upstream product

• 69739-34-0 t-butyldimethylsiyl triflate 
• 185411-09-0 C₁₉H₃₀O₈ 
• 871360-14-4 C₁₈H₂₆O₇ 
• 871360-33-7 [(2R,4aS,6S,7S,8R,8aR)-7,8-Dihydroxy-6-((E)-(S)-1-hydroxy-3-trimethylsilanyl-allyl)-octahydro-pyrano[3,2-b]pyran-2-yl]-acetic acid methyl ester 
• 185411-10-3 C₂₃H₃₈O₇Si 
• 185411-07-8 C₂₇H₄₀O₉ 
• 185411-08-9 C₂₅H₃₈O₈ 
• 185411-06-7 C₂₃H₃₄O₉ 
• 185411-11-4 {(2R,4aS,6S,7R,8S,8aS)-7,8-Bis-(tert-butyl-dimethyl-silanyloxy)-6-[(E)-(S)-1-(tert-butyl-dimethyl-silanyloxy)-3-trimethylsilanyl-allyl]-octahydro-pyrano[3,2-b]pyran-2-yl}-acetic acid methyl ester 

Relevant academic research and scientific papers

PROCESS FOR PREPARATION OF ERIBULIN AND INTERMEDIATES THEREOF

The present application relate to process for preparation of octahydropyrano [3, 2-b] pyran compound of formula II, which is useful as an intermediate for the preparation of halichondrin B analogues such as Eribulin or its pharmaceutically acceptable salts.

INTERMEDIATES FOR THE PREPARATION OF HALICHONDRIN B

The present invention provides macrocyclic compounds, synthesis of the same and intermediates thereto. Such compounds, and compositions thereof, are useful for treating or preventing proliferative disorders Formula (F-4).

Synthetic studies on halichondrins: A practical synthesis of the C.1-C.13 segment

A practical, scalable synthesis of the C.1-C.13 segment of halichondrin B has been developed starting from L-mannonic-γ-lactone, using C-allylation/oxy-Michael cyclization and Ni(II)/Cr(II)-mediated vinyltrimethylsilane addition to set the C.6/C.3 and C.11 stereocenters, respectively.